These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
442 related articles for article (PubMed ID: 34852840)
1. Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab. De Filippi R; Morabito F; Santoro A; Tripepi G; D'Alò F; Rigacci L; Ricci F; Morelli E; Zinzani PL; Pinto A J Transl Med; 2021 Dec; 19(1):489. PubMed ID: 34852840 [TBL] [Abstract][Full Text] [Related]
2. Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events. Cortellini A; Bersanelli M; Santini D; Buti S; Tiseo M; Cannita K; Perrone F; Giusti R; De Tursi M; Zoratto F; Marconcini R; Russano M; Zeppola T; Anesi C; Filetti M; Marchetti P; Botticelli A; Gelibter A; De Galitiis F; Vitale MG; Rastelli F; Tudini M; Silva RR; Atzori F; Chiari R; Ricciuti B; De Giglio A; Migliorino MR; Mallardo D; Vanella V; Mosillo C; Bracarda S; Rinaldi S; Berardi R; Natoli C; Ficorella C; Porzio G; Ascierto PA Eur J Cancer; 2020 Mar; 128():17-26. PubMed ID: 32109847 [TBL] [Abstract][Full Text] [Related]
3. Outcomes and Toxicities of Programmed Death-1 (PD-1) Inhibitors in Hodgkin Lymphoma Patients in the United States: A Real-World, Multicenter Retrospective Analysis. Bair SM; Strelec LE; Feldman TA; Ahmed G; Armand P; Shah NN; Singavi AN; Reddy N; Khan N; Andreadis C; Vu K; Huntington SF; Giri S; Ujjani C; Howlett C; Faheem M; Youngman MR; Nasta SD; Landsburg DJ; Schuster SJ; Svoboda J Oncologist; 2019 Jul; 24(7):955-962. PubMed ID: 30568021 [TBL] [Abstract][Full Text] [Related]
4. Association of Body Mass Index With the Safety Profile of Nivolumab With or Without Ipilimumab. McQuade JL; Hammers H; Furberg H; Engert A; André T; Blumenschein G; Tannir N; Baron A; Larkin J; El-Khoueiry A; Carbone DP; Thomas JM; Hennicken D; Coffey M; Motzer RJ JAMA Oncol; 2023 Jan; 9(1):102-111. PubMed ID: 36480191 [TBL] [Abstract][Full Text] [Related]
5. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505 [TBL] [Abstract][Full Text] [Related]
6. A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. Cortellini A; Bersanelli M; Buti S; Cannita K; Santini D; Perrone F; Giusti R; Tiseo M; Michiara M; Di Marino P; Tinari N; De Tursi M; Zoratto F; Veltri E; Marconcini R; Malorgio F; Russano M; Anesi C; Zeppola T; Filetti M; Marchetti P; Botticelli A; Antonini Cappellini GC; De Galitiis F; Vitale MG; Rastelli F; Pergolesi F; Berardi R; Rinaldi S; Tudini M; Silva RR; Pireddu A; Atzori F; Chiari R; Ricciuti B; De Giglio A; Iacono D; Gelibter A; Occhipinti MA; Parisi A; Porzio G; Fargnoli MC; Ascierto PA; Ficorella C; Natoli C J Immunother Cancer; 2019 Feb; 7(1):57. PubMed ID: 30813970 [TBL] [Abstract][Full Text] [Related]
7. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Rogado J; Sánchez-Torres JM; Romero-Laorden N; Ballesteros AI; Pacheco-Barcia V; Ramos-Leví A; Arranz R; Lorenzo A; Gullón P; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondéjar R; Colomer R Eur J Cancer; 2019 Mar; 109():21-27. PubMed ID: 30682533 [TBL] [Abstract][Full Text] [Related]
8. Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies. Rogado J; Romero-Laorden N; Sanchez-Torres JM; Ramos-Levi AM; Pacheco-Barcia V; Ballesteros AI; Arranz R; Lorenzo A; Gullon P; Garrido A; Serra López-Matencio JM; Donnay O; Adrados M; Costas P; Aspa J; Alfranca A; Mondejar R; Colomer R Oncoimmunology; 2020; 9(1):1751548. PubMed ID: 32363123 [TBL] [Abstract][Full Text] [Related]
9. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. Indini A; Di Guardo L; Cimminiello C; Prisciandaro M; Randon G; De Braud F; Del Vecchio M J Cancer Res Clin Oncol; 2019 Feb; 145(2):511-521. PubMed ID: 30539281 [TBL] [Abstract][Full Text] [Related]
10. Profiling Preexisting Antibodies in Patients Treated With Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. Toi Y; Sugawara S; Sugisaka J; Ono H; Kawashima Y; Aiba T; Kawana S; Saito R; Aso M; Tsurumi K; Suzuki K; Shimizu H; Domeki Y; Terayama K; Nakamura A; Yamanda S; Kimura Y; Honda Y JAMA Oncol; 2019 Mar; 5(3):376-383. PubMed ID: 30589930 [TBL] [Abstract][Full Text] [Related]
11. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis. Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406 [TBL] [Abstract][Full Text] [Related]
12. Impact of aging on immune-related adverse events generated by anti-programmed death (ligand)PD-(L)1 therapies. Baldini C; Martin Romano P; Voisin AL; Danlos FX; Champiat S; Laghouati S; Kfoury M; Vincent H; Postel-Vinay S; Varga A; Vuagnat P; Ribrag V; Mezquita L; Besse B; Hollebecque A; Lambotte O; Michot JM; Soria JC; Massard C; Marabelle A Eur J Cancer; 2020 Apr; 129():71-79. PubMed ID: 32143106 [TBL] [Abstract][Full Text] [Related]
13. Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. Ramchandren R; Domingo-Domènech E; Rueda A; Trněný M; Feldman TA; Lee HJ; Provencio M; Sillaber C; Cohen JB; Savage KJ; Willenbacher W; Ligon AH; Ouyang J; Redd R; Rodig SJ; Shipp MA; Sacchi M; Sumbul A; Armand P; Ansell SM J Clin Oncol; 2019 Aug; 37(23):1997-2007. PubMed ID: 31112476 [TBL] [Abstract][Full Text] [Related]
14. Correlation between immune-related adverse events and prognosis in patients with gastric cancer treated with nivolumab. Masuda K; Shoji H; Nagashima K; Yamamoto S; Ishikawa M; Imazeki H; Aoki M; Miyamoto T; Hirano H; Honma Y; Iwasa S; Okita N; Takashima A; Kato K; Boku N BMC Cancer; 2019 Oct; 19(1):974. PubMed ID: 31638948 [TBL] [Abstract][Full Text] [Related]
15. Clinical, Imaging Findings, Responses, and Outcomes of Patients With Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma Undergoing Immune Checkpoint Inhibitor Therapy: A Single-Institution Experience. Liput J; Guler E; Smith DA; Tirumani SH; Hoimes C; Caimi PF; Ramaiya NH J Comput Assist Tomogr; 2020; 44(4):619-626. PubMed ID: 32558769 [TBL] [Abstract][Full Text] [Related]
16. Occurrence and number of immune-related adverse events are independently associated with survival in advanced non-small-cell lung cancer treated by nivolumab. Bouhlel L; Doyen J; Chamorey E; Poudenx M; Ilie M; Gal J; Guigay J; Benzaquen J; Marquette CH; Berthet JP; Mouroux J; Schiappa R; Padovani B; Hofman P; Otto J Bull Cancer; 2020 Sep; 107(9):946-958. PubMed ID: 32646604 [TBL] [Abstract][Full Text] [Related]
17. Real-World Multicenter Study of PD-1 Blockade in HIV-Associated Classical Hodgkin Lymphoma Across the United States. Lurain K; Zarif TE; Ramaswami R; Nassar AH; Adib E; Abdel-Wahab N; Chintapally N; Drolen CE; Feldman T; Haykal T; Nebhan CA; Kambhampati S; Li M; Mittra A; Lorentsen M; Kim C; Drakaki A; Morse M; Johnson DB; Mangla A; Dittus C; Ravi P; Baiocchi RA; Chiao EY; Rubinstein PG; Yellapragada SV; LaCasce AS; Sonpavde GP; Naqash AR; Herrera AF Clin Lymphoma Myeloma Leuk; 2024 Aug; 24(8):523-530. PubMed ID: 38714474 [TBL] [Abstract][Full Text] [Related]
18. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. Roemer MGM; Redd RA; Cader FZ; Pak CJ; Abdelrahman S; Ouyang J; Sasse S; Younes A; Fanale M; Santoro A; Zinzani PL; Timmerman J; Collins GP; Ramchandren R; Cohen JB; De Boer JP; Kuruvilla J; Savage KJ; Trneny M; Ansell S; Kato K; Farsaci B; Sumbul A; Armand P; Neuberg DS; Pinkus GS; Ligon AH; Rodig SJ; Shipp MA J Clin Oncol; 2018 Apr; 36(10):942-950. PubMed ID: 29394125 [TBL] [Abstract][Full Text] [Related]
19. Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy. Das S; Ciombor KK; Haraldsdottir S; Pumpalova Y; Sahin IH; Pineda G; Shyr Y; Lin EP; Hsu CY; Chu SK; Goff LW; Cardin DB; Bilen MA; Fisher GA; Wu C; Berlin J Oncologist; 2020 Aug; 25(8):669-679. PubMed ID: 31943525 [TBL] [Abstract][Full Text] [Related]
20. A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. Abedian Kalkhoran H; Zwaveling J; Storm BN; van Laar SA; Portielje JE; Codrington H; Luijten D; Brocken P; Smit EF; Visser LE BMC Cancer; 2023 Mar; 23(1):247. PubMed ID: 36918817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]